The SickKids Genome Clinic: Developing and evaluating a pediatric model for individualized genomic medicine

Clinical Genetics

Volumn 89, Issue 1, 2016, Pages 10-19

  Bowdin, S C ^a,b   Hayeems, R Z ^a,c   Monfared, N ^a   Cohn, R D ^a,b   Meyn, M S ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Individualized genomic medicine; Next generation sequencing; Pediatrics; Whole exome; Whole genome

Indexed keywords

BIOINFORMATICS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; ETHICS; GENETIC DISORDER; GENOME ANALYSIS; GENOMICS; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SERVICE; LABORATORY TEST; NEXT GENERATION SEQUENCING; PATIENT PREFERENCE; PEDIATRICS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; HUMAN GENOME; MEDICAL ETHICS; MEDICAL GENETICS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; TRENDS;

ETHICS, MEDICAL; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETICS, MEDICAL; GENOME, HUMAN; GENOMICS; HUMANS; PEDIATRICS; PRECISION MEDICINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84955098960     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12579     Document Type: Review

References (56)

1. Saunders CJ, Miller NA, Soden SE et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med 2012: 4 (154): 154ra135.
2. Yang Y, Muzny DM, Xia F et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014: 312: 1870-1879.
3. Park JY, Clark P, Londin E, Sponziello M, Kricka LJ, Fortina P et al. Clinical exome performance for reporting secondary genetic findings. Clin Chem 2015: 61: 213-220.
4. Claes KB, De Leeneer K. Dealing with pseudogenes in molecular diagnostics in the next-generation sequencing era. Methods Mol Biol 2014: 1167: 303-315.
5. Lee H, Schatz MC. Genomic dark matter: the reliability of short read mapping illustrated by the genome mappability score. Bioinformatics 2012: 28: 2097-2105.
6. Cohen AS, Wilson SL, Trinh J, Ye XC. Detecting somatic mosaicism: considerations and clinical implications. Clin Genet 2014: doi: 10.1111/cge.12502.
7. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012: 40: W452-W457.
8. Gray VE, Kukurba KR, Kumar S. Performance of computational tools in evaluating the functional impact of laboratory-induced amino acid mutations. Bioinformatics 2012: 28: 2093-2096.
9. Wu J, Li Y, Jiang R. Integrating multiple genomic data to predict disease-causing nonsynonymous single nucleotide variants in exome sequencing studies. PLoS Genet 2014: 10: e1004237.
10. Gnad F, Baucom A, Mukhyala K, Manning G, Zhang Z. Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genomics 2013: 14 (Suppl. 3): S7.
11. Millot GA, Carvalho MA, Caputo SM et al. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat 2012: 33: 1526-1537.
12. Tong MY, Cassa CA, Kohane IS. Automated validation of genetic variants from large databases: ensuring that variant references refer to the same genomic locations. Bioinformatics 2011: 27: 891-893.
13. Bell CJ, Dinwiddie DL, Miller NA et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011: 3: 65ra64.
14. Cassa CA, Tong MY, Jordan DM. Large numbers of genetic variants considered to be pathogenic are common in asymptomatic individuals. Hum Mutat 2013: 34: 1216-1220.
15. ClinGen-Clinical Genome Resource. Retrieved March 6, 2015, from http://clinicalgenome.org.
16. Fu W, O'Connor TD, Jun G et al. Analysis of 6, 515 exomes reveals the recent origin of most human protein-coding variants. Nature 2013: 493: 216-220.
17. Gao F, Keinan A. High burden of private mutations due to explosive human population growth and purifying selection. BMC Genomics 2014: 15 (Suppl. 4): S3.
18. Johnston JJ, Rubinstein WS, Facio FM et al. Secondary variants in individuals undergoing exome sequencing: Screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 2012: 91: 97-108.
19. Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem 2012: 58: 1636-1643.
20. Botkin JR, Teutsch SM, Kaye CI et al. Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med 2010: 12: 228-235.
21. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. The EGAPP initiative: lessons learned. Genet Med 2014: 16: 217-224.
22. Szego MJ, Meyn MS, Anderson JA et al. Predictive genomic testing of children for adult onset disorders: a Canadian perspective. Am J Bioeth 2014: 14: 19-21.
23. Anderson JA, Hayeems RZ, Shuman C et al. Predictive genetic testing for adult-onset disorders in minors: a critical analysis of the arguments for and against the 2013 ACMG guidelines. Clin Genet 2014: doi: 10.1111/cge.12460.
24. Borry P, Stultiens L, Nys H, Cassiman JJ, Dierickx K. Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet 2006: 70: 374-381.
25. Burke W, Antommaria AH, Bennett R et al. Recommendations for returning genomic incidental findings? We need to talk!. Genet Med 2013: 15: 854-859.
26. Wolf SM. Return of individual research results and incidental findings: facing the challenges of translational science. Annu Rev Genomics Hum Genet 2013: 14: 557-577.
27. American College of Medical Genetics Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med 2015: 17: 68-69.
28. Genetic Information Nondiscrimination Act of 2008. United States of America, 2008: 122 STAT. 881.
29. Caulfield T, Evans J, McGuire A et al. Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate. PLoS Biol 2013: 11: e1001699.
30. Watson M. Illuminating the future of DNA sequencing. Genome Biol 2014: 15: 108.
31. Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med 2014: doi: 10.1038/gim.2014.156.
32. Girdea M, Dumitriu S, Fiume M et al. PhenoTips: patient phenotyping software for clinical and research use. Hum Mutat 2013: 34: 1057-1065.
33. Bean LJ, Tinker SW, da Silva C, Hegde MR. Free the data: one laboratory's approach to knowledge-based genomic variant classification and preparation for EMR integration of genomic data. Hum Mutat 2013: 34: 1183-1188.
34. Jacob HJ, Abrams K, Bick DP et al. Genomics in clinical practice: lessons from the front lines. Sci Transl Med 2013: 5: 194cm195.
35. Worthey EA. Analysis and annotation of whole-genome or whole-exome sequencing-derived variants for clinical diagnosis. Curr Protoc Hum Genet 2013: 79 (Unit 9): 24.
36. Fiume M, Smith EJ, Brook A et al. Savant Genome Browser 2: visualization and analysis for population-scale genomics. Nucleic Acids Res 2012: 40: W615-W621.
37. Terry SF. The global alliance for genomics & health. Genet Test Mol Biomarkers 2014: 18: 375-376.
38. Solomon BD, Nguyen AD, Bear KA, Wolfsberg TG. Clinical genomic database. Proc Natl Acad Sci U S A 2013: 110: 9851-9855.
39. Tabor HK, Stock J, Brazg T et al. Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. Am J Med Genet A 2012: 158A: 1310-1319.
40. Mayer AN, Dimmock DP, Arca MJ et al. A timely arrival for genomic medicine. Genet Med 2011: 13: 195-196.
41. Fitzpatrick JL, Hahn C, Costa T, Huggins MJ. The duty to recontact: attitudes of genetics service providers. Am J Hum Genet 1999: 64: 852-860.
42. Hunter AG, Sharpe N, Mullen M, Meschino WS. Ethical, legal, and practical concerns about recontacting patients to inform them of new information: the case in medical genetics. Am J Med Genet 2001: 103: 265-276.
43. Dreyfuss JM, Levner D, Galagan JE, Church GM, Ramoni MF. How accurate can genetic predictions be? BMC Genomics 2012: 13: 340.
44. Lawrence L, Sincan M, Markello T et al. The implications of familial incidental findings from exome sequencing: the NIH Undiagnosed Diseases Program experience. Genet Med 2014: 16: 741-750.
45. Vitazka P, Neidrich J, Scufins J et al. Update on evaluation of ACMG recommended incidental findings in clinical whole exome sequencing. 64th Annual Meeting of the American Society of Human Genetics, San Diego, CA, 2014: 598.
46. ®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Maryland). Retrieved March 6th, 2015, from http://www.omim.org.
47. Ding LE, Burnett L, Chesher D. The impact of reporting incidental findings from exome and whole-genome sequencing: predicted frequencies based on modeling. Genet Med 2015: 17: 197-204.
48. Office of Rare Diseases Research. Frequently asked questions. Retrieved March 6th, 2015, from http://rarediseases.info.nih.gov/about-ordr/pages/31/frequently-asked-questions.
49. Johnston JJ, Lewis K, Ng D et al. Individualized iterative phenotyping for genome-wide analysis of loss of function mutations. 64th Annual Meeting of the American Society of the Human Genetics, San Diego, CA, 2014: 46.
50. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. The predictive capacity of personal genome sequencing. Sci Transl Med 2012: 4: 133ra158.
51. Do CB, Hinds DA, Francke U, Eriksson N. Comparison of family history and SNPs for predicting risk of complex disease. PLoS Genet 2012: 8: e1002973.
52. Ball RD. Experimental designs for robust detection of effects in genome-wide case-control studies. Genetics 2011: 189: 1497-1514.
53. Chatterjee N, Wheeler B, Sampson J, Hartge P, Chanock SJ, Park JH. Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies. Nat Genet 2013: 45 400-405, 405e401-403.
54. Pharoah PD, Antoniou AC, Easton DF et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008: 358: 2796-2803.
55. Wikipedia. Hype cycle. 2015. Retrieved March 6th, 2015, from http://en.wikipedia.org/wiki/Hype_cycle.
56. National Human Genome Research Institute Clinical Sequencing Exploratory Research (CSER). 2014. Retrieved March 6th, 2015, from http://www.genome.gov/27546194.